ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1629

Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study

María Carmen García-Gómez1, Maria Auxiliadora Martin2, Cristina Fernández-Carballido3, Santos Castañeda4, Carlos González-Juanatey5, Fernando Sánchez-Alonso6, María José González-Fernández7, Raimon Sanmarti8, Alberto Garcia-Vadillo9, Benjamin Fernandez Gutierrez10, Miriam García-Arias11, Javier Manero12, José Miguel Senabre13, Amalia Rueda Cid14, Sergio Ros Expósito15, José Manuel Pina Salvador16, Alba Erra Durán17, Ingrid Moller18, Javier Llorca19 and Miguel Angel González-Gay20, 1Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, 2Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, 3Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, 4Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, 5Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, 6Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, 7Rheumatology, Institut Dexeus, Barcelona, Spain, 8Rheumatology Service, Hospital Clinic, Barcelona, Spain, 9Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 10Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, 11Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, 12Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, 13Rheumatology, Hospital Marina Baixa, Alicante, Spain, 14Rheumatology, Hospital General de Valencia, Valencia, Spain, 15Rheumatology, Hospital de Viladecans, Barcelona, Spain, 16Rheumatology, Hospital de Barbastro, Huesca, Spain, 17Rheumatology, Hospital de Sant Rafael, Barcelona, Spain, 18Instituto de Poal, Barcelona, Spain, 19Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, 20School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS), Cardiovascular disease, Lipids, Psoriatic arthritis and spondylarthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, October 22, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Cardiovascular disease (CVD) is one of the main cause of mortality and morbidity in patients with spondyloarthritis (SpA), partially explained by traditional CV risk factors (CVRF). Other non-conventional CVRF, probably related to chronic systemic inflammation, may be involved. In this sense, lipoprotein (a) [Lp (a)], an non-conventional risk factor with proatherogenic and thrombogenic properties, could be involved, since it seems to act as an acute-phase reactant, however, there are few data on this aspect in these patients. The purpose of this study is to evaluate the prevalence of hyperlipoproteinemia (a) in patients with SpA and analyze the possible related factors.

Methods: Analysis of the baseline visit of patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) of the CARMA project (CARdiovascular in Reumatology), a prospective cohort study of 10 years of follow-up, to evaluate the cardiovascular risk in chronic rheumatic inflammatory diseases, including rheumatoid arthritis, AS and PsA, followed in 67 Spanish rheumatology centers. A multivariate logistic regression model was performed, in which the dependent variable was hyperliproteinemia (a), defined as the plasma concentration of lipoprotein (a) [Lp (a)] > 50 mg/dl. Sociodemographic factors and those related to the disease itself, classic CVRF, lipid profile and apolipoproteins, and treatments have been included as independent variables.

Results: 1459 patients were analyzed, 738 with AS and 721 with PsA, and 677 controls. Plasma concentrations of Lp(a) were available in 57.7% of the patients with AS and in 57.1% of the patients with PsA, and in 58% of the controls. A 19.2% (95% CI: 16.80-22.05) of the patients with SpA, 20.7% (95% CI: 16.91-24.82) of AS and 17.7% (95% CI: 14.15-21.75) of PsA, respectively, and a 16.7% (95% CI: 13.23-20.86; p=0.326) of the control group, had hyperlipoproteinemia (a), without statistically significant differences between groups. After adjusting for age and sex, SpA patients were more likely to have hyperlipoproteinemia (a) than control group (OR : 1.43, CI:1.00-2.04; p=0.05), especially in patients with AS (OR: 1.81, 95% CI: 1.18-2.77; p=0.007).In the model adjusted for possible confounding factors, high values of apolipoprotein B in all patients, non-steroidal antiinflammatories in AS, and sex (women) in PsA, were associated with a higher probability of presenting hyperlipoproteinemia (a).

Conclusion: Patients with SpA show a moderately increased risk of hyperliproteinemia (a) compared to the control group, especially in those with AS. No specific factors of the disease have been identified that are associated with hyperlipoproteinemia (a) in each of the analyzed groups. The determination of Lp (a) may be of potential interest to improve the assessment of CV risk in patients with SpA, especially in those with a moderate / high CV risk according to the algorithms of the risk tables.


Disclosure: M. C. García-Gómez, None; M. A. Martin, None; C. Fernández-Carballido, None; S. Castañeda, None; C. González-Juanatey, None; F. Sánchez-Alonso, None; M. J. González-Fernández, None; R. Sanmarti, None; A. Garcia-Vadillo, None; B. Fernandez Gutierrez, None; M. García-Arias, None; J. Manero, None; J. M. Senabre, None; A. Rueda Cid, None; S. Ros Expósito, None; J. M. Pina Salvador, None; A. Erra Durán, None; I. Moller, None; J. Llorca, None; M. A. González-Gay, None.

To cite this abstract in AMA style:

García-Gómez MC, Martin MA, Fernández-Carballido C, Castañeda S, González-Juanatey C, Sánchez-Alonso F, González-Fernández MJ, Sanmarti R, Garcia-Vadillo A, Fernandez Gutierrez B, García-Arias M, Manero J, Senabre JM, Rueda Cid A, Ros Expósito S, Pina Salvador JM, Erra Durán A, Moller I, Llorca J, González-Gay MA. Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/hyperlipoproteinemia-a-in-patients-with-spondyloarthritis-results-of-the-carma-study/. Accessed March 4, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyperlipoproteinemia-a-in-patients-with-spondyloarthritis-results-of-the-carma-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.